Janus Henderson Group PLC Sells 187 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Janus Henderson Group PLC reduced its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,647 shares of the company’s stock after selling 187 shares during the period. Janus Henderson Group PLC’s holdings in IDEXX Laboratories were worth $4,817,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the stock. Norges Bank bought a new stake in IDEXX Laboratories during the fourth quarter worth approximately $412,258,000. Flossbach Von Storch SE grew its stake in shares of IDEXX Laboratories by 5,439.3% in the fourth quarter. Flossbach Von Storch SE now owns 473,336 shares of the company’s stock worth $195,696,000 after acquiring an additional 464,791 shares during the last quarter. Alyeska Investment Group L.P. bought a new position in shares of IDEXX Laboratories during the 4th quarter worth about $156,412,000. William Blair Investment Management LLC increased its stake in IDEXX Laboratories by 701.6% during the fourth quarter. William Blair Investment Management LLC now owns 422,133 shares of the company’s stock valued at $174,527,000 after acquiring an additional 369,471 shares during the period. Finally, BNP Paribas Financial Markets raised its stake in shares of IDEXX Laboratories by 221.3% in the fourth quarter. BNP Paribas Financial Markets now owns 441,319 shares of the company’s stock valued at $182,459,000 after purchasing an additional 303,966 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

IDXX has been the topic of a number of recent research reports. Morgan Stanley lifted their price objective on IDEXX Laboratories from $548.00 to $558.00 and gave the company an “overweight” rating in a report on Monday, May 5th. Bank of America upped their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. Stifel Nicolaus lowered their price objective on IDEXX Laboratories from $450.00 to $420.00 and set a “hold” rating for the company in a research report on Monday, April 14th. StockNews.com upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Friday, May 9th. Finally, Barclays upped their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research note on Tuesday, February 4th. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and a consensus target price of $524.75.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $518.10 on Monday. The firm has a market cap of $41.67 billion, a PE ratio of 48.56, a P/E/G ratio of 3.41 and a beta of 1.52. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $545.43. The company’s fifty day simple moving average is $431.28 and its 200-day simple moving average is $431.45. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, beating analysts’ consensus estimates of $2.93 by $0.03. The firm had revenue of $998.43 million during the quarter, compared to the consensus estimate of $998.25 million. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The business’s revenue was up 3.6% compared to the same quarter last year. During the same period last year, the company earned $2.71 earnings per share. Equities research analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.